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Abstract: The aim of the present study was to prepare valdecoxib, a cyclo-oxygenase-2 enzyme 
inhibitor, as a loaded multiparticulate system to achieve site-specific drug delivery to colorectal 
tumors. Film coating was done with the pH-sensitive polymer Eudragit S100 and sodium alginate 
was used as mucoadhesive polymer in the core. The microspheres were characterized by X-ray 
diffraction, differential scanning calorimetry, and Fourier transform infrared spectroscopy and 
were evaluated for particle size, drug load, in vitro drug release, release kinetics, accelerated 
stability, and extent of mucoadhesion. The coated microspheres released the drug at pH 7.4, 
the putative parameter for colonic delivery. When applied to the mucosal surface of freshly 
excised goat colon, microspheres pretreated with phosphate buffer pH 7.4 for 30 minutes showed 
mucoadhesion. To ascertain the effect of valdecoxib on the viability of Caco-2 cells, the 3-(4,5-
dimethylthiazol-2yl) 2,5-diphenyltetrazolium bromide) test was conducted using both valdecoxib 
and coated microspheres. In both cases, the percentage of dehydrogenase activity indicated a 
lack of toxicity against Caco-2 cells in the tested concentration range. Drug transport studies 
of the drug as well as the coated microspheres in buffers of pH 6 and 7.4 across Caco-2 cell 
monolayers were conducted. The microspheres were found to exhibit slower and delayed drug 
release and lower intracellular concentration of valdecoxib.
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Introduction
Colorectal cancer is the third most common malignancy and the fourth most frequent 
cause of cancer deaths worldwide, with 945,000 estimated new cases and 492,000 
deaths per year in industrialized countries, where the lifetime incidence of the disease 
is 5%.1 Development of colorectal cancer is reported to be associated with multiple 
factors, which include, among others, acquired and inherited genetic susceptibility, 
environmental elements, and lifestyle choices.2 Chronic ulcerative colitis, particularly 
when it involves the entire large intestine, predisposes individuals to colorectal cancer 
at a rate that is 4- to 20-fold greater than average.3 There are three specific patterns in 
which colon cancer is generally observed: sporadic, inherited, and familial. Although 
the majority of cases of colon cancer are sporadic in nature, as many as 10% of cases 
are thought to be hereditary. The two most common forms of hereditary colon cancer 
are the familial adenomatous polyposis and the hereditary nonpolyposis colorectal 
cancer, both of which result from a specific germline mutation.4
Studies have consistently demonstrated that regular use (at least two doses per 
week) of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced 
risk of colorectal cancer.5 The conventional NSAIDs, such as aspirin, diclofenac, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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ibuprofen, and others, are reported to inhibit both the COX-1 
and COX-2 forms of the enzyme cyclo-oxygenase (COX). 
The COX-1 enzyme is required for physiological processes 
such as maintenance of gastrointestinal mucosa and platelet 
aggregation. However, the potential mechanisms by which 
these NSAIDs exert their protective effects in colorectal 
cancer appear to be linked primarily to their inhibition of the 
enzyme COX-2 and free-radical formation. COX-2 overex-
pression is seen in precancerous and cancerous lesions in the 
colon and is associated with a decrease in colon cancer cell 
apoptosis, as well as enhanced production of angiogenesis-
promoting factors.6 However, the dual COX inhibitory effect 
of the conventional NSAIDs results in gastrointestinal side 
effects, and hence these are not recommended to be used in 
the prevention of colorectal cancer. Specific inhibitors of 
the enzyme COX-2, such as valdecoxib and celecoxib, are 
quite selective in their action and hence are recommended 
for the treatment of colorectal cancer. However, some 
recent reports have focused on the cardiac toxicity of these 
COX-2 inhibitors, and the use of celecoxib, valdecoxib, and 
rofecoxib has been shown to be related to an increased risk 
of myocardial infarction.7 On the other hand, in the APC 
(Adenoma Prevention with Celicoxib) trial, which was 
cosponsored by the National Cancer Institute and Pfizer Inc. 
of New York, it has been shown that cardiovascular problems 
associated with COX-2 inhibitors are more likely to occur 
with patients with previous cardiovascular problems, and 
their use is recommended for chemoprevention in patients 
without cardiovascular risks.8,9
Targeted delivery to the colon is an attempt to delay 
the release of the drug into the colon in order to achieve a 
high local concentration while reducing the dose and thus 
undue side effects of the drug. Researchers have reported 
alkaline pH (∼8.0) of colonic contents in patients suffering 
from colon cancer.10–12 These specific pH conditions of the 
colonic region may enhance the chances to successfully 
deliver the drug to the region by developing a suitable 
pH-dependent system.13–15 Moreover, dosage forms with 
mucoadhesive properties may prolong the residence time 
at the site of drug absorption. Mucoadhesive microparticu-
lates coated with a pH-dependent polymer are proposed 
to initiate the release of the drug at the putative colonic 
pH 7–8.
Microspheres of valdecoxib (a COX-2 inhibitor) dis-
persed in a matrix of sodium alginate and subsequently 
coated with Eudragit S100 (copolymer of methacrylic acid 
and methyl methacrylate, a pH-sensitive polymer) were 
prepared. Characterization of the microspheres was carried 
out by Fourier transform infrared (FTIR) spectroscopy, 
X-ray diffraction (XRD), differential scanning calorimetry 
(DSC), and scanning electron microscopy (SEM). The 
microspheres were evaluated for mucoadhesion, in vitro drug 
release in simulated gastrointestinal conditions, and stability 
of the formulations. Drug transport studies of valdecoxib 
and its coated microspheres were conducted to assess the 
permeability of the drug across the biological membranes 
using Caco-2 monolayers. Also, 3-(4,5-dimethylthiazol-2yl) 
2,5-diphenyltetrazolium bromide test was performed to assess 
the toxicity of valdecoxib to Caco-2 cells in concentrations 
intended to be used in transport studies.
Materials and methods
Materials
Valdecoxib and Eudragit S100 were gifts from Aarti Drugs 
Ltd (Thane, India) and Evonik Industries (Mumbai, India), 
respectively. The following ingredients used in the studies 
were of analytical grade: sodium alginate (molecular weight: 
198.11) and Span 80 (Loba Chemie Pvt. Ltd, Mumbai, India); 
light liquid paraffin, calcium chloride, isopropyl alcohol 
(IPA), potassium dihydrogen phosphate, disodium hydrogen 
phosphate, and sodium hydroxide (Merck Specialities Pvt. 
Ltd, Mumbai, India); petroleum ether (RFCL Ltd, New Delhi, 
India); ethanol (Changshu Chemical, China); methanol (SD 
Fine Chem Ltd, Mumbai, India); isobutanol and hydrochloric 
acid (Merck K GaA, Darmstadt, Germany); 3-(4,5-
dimethylthiazol-2yl) 2,5-diphenyltetrazolium bromide) 
(MTT), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), bovine serum albumin (BSA), 2-(N-morpholino) 
ethanesulfonic acid (MES), and sodium dodecyl sufate (SDS) 
(Sigma-Aldrich Labochemikalien GmbH, Germany); and 
Hank’s buffered salt solution(HBSS) 10x (GIBCO batch 
699997). Acetonitrile (Sigma-Aldrich Labochemikalien 
GmbH) was high-performance liquid chromatography 
(HPLC) grade.
Preparation of core valdecoxib 
microspheres
Core microspheres of valdecoxib in varying drug polymer 
ratios (VSA1–VSA5), as shown in Table 1, were prepared 
following previously published methods.16–18 In a typical 
experiment, a defined quantity of valdecoxib was dispersed 
in aqueous solutions of varying concentrations of sodium 
alginate in accordance with a drug polymer ratio as in 
Table 1. Subsequently, the dispersion was emulsified in light 
liquid paraffin containing 2% v/v Span 80, with the help of 
a mechanical stirrer (Remi Instruments Ltd, Mumbai, India) International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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at 2000 rpm for 1 hour. A specified volume of the calcium 
chloride solution (5% w/v in IPA) (polymer CaCl2 ratio 1:1) 
was then added to the emulsion at a rate of 2 mL/min and the 
emulsion was stirred for 10 more minutes. Microspheres were 
collected by filtration and washed three times with petroleum 
ether to remove the residual liquid paraffin. Microspheres 
were kept in a deep freezer at −50°C for 10 hours and then 
kept in a vacuum desiccator for 12 hours.
encapsulation of core microspheres
Selected formulations of core microspheres were coated with 
two different concentrations of Eudragit S100 viz. core coat 
ratio 1:2.5 and of 1:5 (VSAE-1 and VSAE-2,   respectively). 
Thus, core microspheres were dispersed in Eudragit 
S100 solution (10% w/v) in methanol at room temperature 
followed by emulsification in light liquid paraffin containing 
2% Span 80 in a beaker, with the help of a mechanical stirrer 
(1500–2000 rpm). Stirring was continued for 3 hours at room 
temperature in order to evaporate the solvent completely. 
Encapsulated microspheres were filtered and washed with 
petroleum ether to remove the liquid paraffin and dried in a 
vacuum desiccator for 24 hours.
characterization of valdecoxib 
microsphere
FTIr spectroscopy
FTIR spectra of selected microspheres were recorded using 
a FTIR spectrophotometer (Perkin Elmer model 1600-FTIR) 
in the range of 4000–400 cm−1.
XrD
X-ray diffractograms of the selected microspheres were 
recorded using an X-ray diffractometer (X’Pert Pro, PW 
3050/PW 3071; Lelyweg, the Netherlands) using nickel-
filtered CuKα radiation (λ = 1.540598A°) generated at 
40 kV and 30 mA and scanning rate 2°/min over a 2θ range 
of 10°–80°.
Dsc
Thermal analysis of selected microspheres was performed 
using a DSC-TA system (Perkin Elmer). All samples were 
sealed in a crimped aluminum pan by application of the 
minimum possible pressure and heated at a rate of 10°C/min 
from 40°C to 260°C in a nitrogen atmosphere. An empty 
aluminum pan was utilized as the reference pan.
surface morphology and particle size distribution
The shape and surface characteristics of selected microspheres 
were analyzed by SEM (ZEISS EVO Series Model EVO50 
with a spatial resolution of 2.5 nm). Samples mounted on an 
aluminum stub were sputter coated with gold under reduced 
pressure and a 30–40 nm thick gold coat was applied using 
BIO-RAD POLARAN sputter coater. The sample assembly 
was placed in the microscope and vacuum was applied. The 
microspheres were observed under SEM at an accelerating 
voltage of 15KV .
The particle size distribution of the coated microspheres 
was determined using a Particle Size Analyzer (Brookhaven 
Instruments Corporation, Model 90Plus). The weighed 
microspheres (20 mg) were suspended in double-distilled 
water and the dispersion was examined to determine particle 
size distribution.
Drug loading and drug loading efficiency
Accurately weighed core microspheres equivalent to 20 mg 
of the valdecoxib were dissolved in 100 mL ethanol and 
subjected to centrifugation at 3000 rpm for 10 minutes. The 
supernatant solution was withdrawn and diluted with ethanol 
to a concentration ≈20 µg/mL. Absorbance of the resulting 
solution was measured at 244 nm in an ultraviolet (UV) 
spectrophotometer (Shimadzu UV Pharmaspec 1700), and 
the drug content in microspheres was determined. The same 
procedure was followed for measuring drug content in the 
coated microspheres using 100 mg of coated microspheres. 
The following formulae were employed for the calculation 
of percentage drug loading and drug loading efficiency:
  Drug loading (%) = DM/WM × 100
where DM is drug contents in microspheres and WM is weight 
of microspheres.
Drug loading efficiency (%) =
Drug loaded
Theoretical drug conten nt
×100
Table  1  Various  formulations  of  valdecoxib  microspheres  in 
sodium alginate polymer and their drug loading efficiency
Formulation 
code
Drug:polymer 
ratio
Drug loading 
efficiency (%)
VsA-1 1:10 (400 mg:4 g) 83.80 ± 1.62
VsA-2 1:5 (400 mg:2 g) 38.91 ± 2.12
VsA-3 1:15 (400 mg:6 g) 85.56 ± 1.87
VsA-4 1:10 (600 mg:6 g) 75.50 ± 1.79
VsA-5 1:10 (800 mg:8 g) 74.83 ± 2.06
Coated  
formulations
Core:coat  
ratio
Drug loading   
efficiency (%)
VsAe-1 1:2.5 92.84 ± 1.72
VsAe-2 1:5 93.60 ± 1.65International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Drug release profile
core microspheres
Accurately weighed core microspheres equivalent to 2 mg 
of valdecoxib were suspended in 20 mL of 7.4 pH   phosphate 
buffer containing 1.5% w/v SDS. The mixture was stirred 
magnetically at 37°C at 50 rpm. Samples were withdrawn 
at specified time intervals with volume replacement. 
The   withdrawn samples were centrifuged at 3000 rpm; 
supernatant was filtered through 0.45 µm membrane 
filter, diluted to 10 mL with phosphate buffer pH 7.4, and 
analyzed for drug content by measuring absorbance at 244 nm 
in a UV spectrophotometer. All the experiments were con-
ducted in triplicate.
coated microspheres
Accurately weighed coated microspheres equivalent to 2 mg 
of drug were placed in 20 mL 0.01 N hydrochloric acid 
(pH 2.0) and stirred magnetically at 50 rpm for 2 hours. The 
samples were centrifuged and supernatant filtered through 
0.45 µm membrane filter and analyzed for the drug content 
as described previously.
In a similar experiment, coated microspheres equivalent 
to 2 mg of drug were placed in 20 mL of phosphate   buffer 
containing 1.5% w/v SDS and stirred magnetically at 
50 rpm. The initial pH of the buffer was maintained at 5.5 
for 2 hours, which was increased by the addition of Na2HPO4 
to 6.8 and maintained for 2 hours. Subsequently, the pH of 
the buffer was raised by further addition of Na2HPO4 to 7.4 
and maintained until the completion of study. Hourly, 1 mL 
of the sample was withdrawn, and each withdrawn sample 
was replaced with fresh release medium. The samples 
were   centrifuged and the supernatant was passed through 
a 0.45 µm filter and analyzed for drug content as described 
previously. All the experiments were run in triplicate.
statistical analysis
The in vitro drug release data from microspheres were 
compared by statistical analysis using one-way analysis of 
variance (ANOVA). The Student’s t-test was performed to 
compare the significance of the difference between the means 
of two groups. P , 0.05 was considered significant.
In vitro evaluation of mucoadhesion
The in vitro wash-off test as reported by Lehr et al19 
was   followed for the determination of mucoadhesion of 
microspheres. The proximal large intestine of freshly 
slaughtered goat was cut to expose the mucosal surface and 
washed with distilled water and phosphate buffer pH 7.4. 
The serosal side (2 cm × 2 cm) was fixed with the help of 
thread on a glass slide. Coated microspheres (5 mg) were 
spread on the exposed mucosal surface and rinsed with phos-
phate   buffer pH 7.4 and the assembly was kept in a humidity 
chamber (Thermotech, India, Model TH-7004) at 37°C and 
90%   relative humidity (RH) for a period of 30 minutes. This 
  pretreatment was performed to dissolve the Eudragit S100 coat 
and to expose the core alginate polymer. Subsequently, the 
complete assembly was mounted onto the tablet disintegration 
test apparatus (Veego, India, model VTD-AVP) with the help 
of a clamp and a thread. The apparatus was operated in such 
a manner that the tissue moved regularly up and down at a 
frequency of 28–32 cycles per minute while immersed in the 
phosphate buffer pH 7.4 contained in a 1000 mL beaker. The 
time for complete wash-off of microsphere from the tissue 
was considered the mucoadhesion time.
In vitro transport studies across 
caco-2 monolayer
Protocols for culturing Caco-2 cells were as previously 
described.20,21 Caco-2 cells of passage 29 were seeded onto 
Transwell inserts (1.12 cm2, 0.4 µm pore size, 105 cells per 
insert), and all the experiments of transport studies were 
conducted at day 28 after seeding.
For the purpose of conducting the MTT test, approximately 
4 × 104 suspended cells were seeded into each of 96 wells in 
enzyme-linked immunosorbent assay plates (MicroWells, 
Nunk, Denmark). The cells were then cultured under standard 
conditions for 20–24 hours before use.
MTT test
In order to assess the toxicity of valdecoxib and its coated 
microspheres to Caco-2 cells, an MTT test was conducted 
on the Caco-2 cell monolayers as described by Anderberg 
and Artursson.22 The test is based on the principle that the 
enzyme dehydrogenase in the mitochondria of living cells 
converts the yellow MTT (3-[4,5-dimethylthiazol-2yl] 
2,5-diphenyltetrazolium bromide) to a blue–purple   formazan 
crystal.23 If the cells are exposed to adverse treatment 
affecting their viability, the activity of the dehydrogenase 
enzyme is compromised.
Valdecoxib solutions and the coated microspheres were 
tested in eight concentrations (0.318–31.8 nM/mL). All the 
solutions were prepared a day before the experiment in 
HBSS. SDS (concentration ranging from 0.05 mM/mL to 
5.0 mM/mL) was included as a positive control, and blank 
HBSS served as a negative control. HBSS was placed in 
cell-free wells as an additional background control.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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On the day of the experiment, the cells were examined 
under microscope to ensure that they were attached to the 
bottom of the wells. The medium was discarded and the test 
solutions, positive, negative, and background controls, were 
transferred to the 96-well tray. All solutions were tested in 
triplicate. The tray was incubated at 37°C on a shaker table at 
100 rpm (Edmund Bühler GmbH) for 4 hours. Next, the wells 
were emptied and 100 µL of HBSS was added to all the wells 
along with 20 µL MTT solution (5 mg/mL). The tray was 
wrapped in tin foil and incubated for 90 minutes at 37°C and 
100 rpm (on the shaker table). At this time, insoluble blue–
purple formazan crystals formed. Subsequently, 100 µL of 
solvent containing SDS (11%w/v), isobutanol (50%v/v), and 
0.02 N hydrochloric acid (50%v/v) was added to all the wells, 
and the tray was again wrapped in tin foil and set aside on 
a shaker table at 37°C overnight, to allow dissolution of the 
blue–purple crystals. On the following day, the absorbance 
was measured at 595 nm using a plate reader (Labsystems 
Multiskan MS).
Drug transport studies across caco-2 monolayer
The transport of valdecoxib across the Caco-2 cell monolayer 
was determined using HBSS as a medium supplemented 
with 1% BSA and 10 mM MES (pH 6.0; 2-(N-morpholino) 
ethanesulfonic acid) or 10 mM HEPES (pH 7.4; 4-2-
hydroxyethyl-1-piperazineethanesulfonic acid). Before 
initiation of experiments and after the completion of the 
experiment, the barrier properties of the Caco-2 monolayers 
were assessed by transepithelial electrical resistance 
(TEER) measured at room temperature (25°C) in a   tissue 
resistance measurement chamber (EndOhm) with a 
voltmeter (EVOM), both of which were from World Preci-
sion Instruments (Sarasota, FL). The cell monolayers were 
rinsed once in prewarmed HBSS, placed on a shaking plate, 
and heated to 37°C. The apical side was filled with 500 µL 
of drug solution (10 µg/mL or 31.81 nmol/ml) prepared in 
the aforementioned medium, and the basolateral side was 
filled with 1 mL of the medium. Samples (100 µL) from 
the apical solution were withdrawn at the start and end of 
the assays. Samples (100 µL) from the basolateral solu-
tion were withdrawn regularly at 30-minute intervals and 
replaced each time with the same amount of fresh buffer. 
Sampling was conducted for a period of 120 minutes for the 
valdecoxib drug solution and for a period of 240 minutes for 
the valdecoxib microspheres, in anticipation of the longer 
time required for drug release from them, as inferred from 
the in vitro drug release results. Transport of valdecoxib 
from solution and microspheres was investigated at both 
pH 6.0 and pH 7.4. All the experiments were performed 
in triplicate.
Estimation of the intracellular contents of the drug after the 
transport study was conducted by washing the cells along with 
supporting membrane twice with HBSS buffer and subsequent 
air-drying. Further, the individual supporting membrane, 
along with cells, was scraped out using a sharp scalpel and was 
kept in plastic centrifuge vials prefilled with 1 mL acetonitrile. 
All the centrifuge vials were swirled for 10 minutes and then 
centrifuged (Biofuge-15, Heraeus-Sepatech) at 4000 rpm for 
10 minutes. The supernatant from all the vials was subjected 
to drug content analysis by HPLC.
Samples were transferred to HPLC vials and frozen until 
further analysis. The samples were analyzed using a method 
reported by Fronza et al24 using a Merck-Hitachi HPLC 
  system, with pump (L-7100), auto-sampler (L-7200), interface 
D-7000, UV detector L-7400, and column oven L-7350.
stability studies
In order to assess long-term stability, three different batches 
of formulations for VSAE-2 were subjected to stability 
studies as per International Conference on Harmonisation 
(ICH) guidelines. Coated microspheres were wrapped in 
aluminum foil laminated on the inside with polyethylene. 
The samples were kept at 40°C ± 2°C/75% RH ± 5% in 
a stability chamber (Scope Enterprises, Delhi, India) for a 
period of 6 months. Samples were withdrawn after an interval 
of 15 days, 30 days, 90 days, and 180 days and were analyzed 
for drug content.
Results and discussion
characterization of microspheres
FTIr spectroscopy
FTIR spectra of the drug valdecoxib, sodium alginate, 
Eudragit S100, and the coated microspheres are presented 
in Figure 1. FTIR spectrum of the pure valdecoxib showed 
characteristic peaks at 3377 cm−1 and 3250 cm−1 due to N-H 
stretching of sulfonamide and at 1334 cm−1 and 1150 cm−1 
due to S=O stretching vibrations of sulfonamide. The spec-
trum of Eudragit S100-coated microspheres of valdecoxib 
containing sodium alginate showed peaks at 3377 cm−1 and 
3250 cm−1 due to valdecoxib, at 1728 cm−1 due to Eudragit 
S100, at 1620 cm−1 due to sodium alginate, and at 1334 cm−1 
and 1155 cm−1 due to valdecoxib and Eudragit S100.
XrD
X-ray diffractograms (Figure 2) of valdecoxib indicated the 
presence of a crystalline material with principal peaks at International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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22.45° and 24.35° 2θ, whereas both the polymers sodium 
alginate and Eudragit S100 were found to be amorphous. 
Although the diffractogram of core microspheres of 
valdecoxib demonstrated the presence of crystalline drug 
embedded in the amorphous polymer, the diffractogram of 
coated microspheres showed an amorphous material devoid 
of any crystallinity. This could be attributed to a dilution 
effect by the amorphous polymers.
Dsc
DSC thermograms of the drug, polymers, and microspheres 
are presented in Figure 3. Pure valdecoxib exhibited a melting 
endotherm at 174.25°C. However, thermograms of the coated 
microspheres demonstrated a depressed, relatively broad 
endotherm at 168.38°C, which could be attributed to the 
dilution effect of the amorphous polymers.
surface morphology and particle size distribution
SEM of core valdecoxib microspheres in sodium alginate 
(Figure 4) revealed mostly spherical, rough-surfaced 
microspheres, the rough surface being indicative of the 
surface-associated drug crystals. On the other hand, SEM 
of the coated microspheres of valdecoxib in sodium alginate 
revealed mostly spherical and smooth-surfaced microspheres. 
The average diameter of the coated microspheres in sodium 
alginate was found to be 35.59 µm (22.67–46.51 µm).
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Figure 1 Fourier transform infrared spectra of valdecoxib, eudragit s100, sodium alginate, and the coated microspheres (VsAe-2).
Valdecoxib powder
Sod. alg powder
Eudragit S100 powder
Phy mix valde sod alg
Core valde microsph in sod alg
Valde sod alg eu S100 phy mix
Valdecoxib micro sod alg eu S100
2000
1000
1000
1000
1000
1000
500
500
500
500
0
0
0
0
0
0
20 30 40 50 60 70
0
400
Position [°2θ]
Counts
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Drug loading efficiency
The drug loading efficiency of various formulations is pre-
sented in Table 1. Retrofit analysis of the data reveals that 
increasing the drug polymer ratio from 1:5 to 1:15 resulted in 
an increased drug loading efficiency. However, the extent of 
the increase was not substantial beyond the drug polymer ratio 
1:10. Hence, it was kept constant, and the quantity of drug and 
polymer were varied for compositions VSA-1, VSA-4, and 
VSA-5.   Composition corresponding to composition VSA-1 
was utilized for further studies incorporating coating with 
Eudragit S100 polymer in the core:coat ratio of 1:2.5 (VSAE-1) 
and 1:5 (VSAE-2). The drug loading efficiency in core micro-
spheres of VSA-1 was 83.80% ± 1.62%, which is comparable 
with that of the core microspheres of chitosan, where it was 
80.33% ± 2.24%, as reported in a previous publication.18
In vitro release profile
core microspheres
The in vitro release profiles of microspheres containing 
varying ratios of drug:sodium alginate as core, are presented 
in Figure 5. ANOVA showed that there was no significant 
difference in the rate and extent of drug release from the 
formulations VSA1, VSA4, and VSA5 (P . 0.05), indicating 
that changing the quantity of polymer (sodium alginate) and 
drug, keeping their ratio constant, does not change the in vitro 
release profile of the microspheres. ANOVAs of VSA1, 
VSA2, and VSA3 indicated the significant difference in rate 
and extent of drug release (P , 0.05). The t-test indicated that 
rate and extent of drug release of VSA1 ≠ VSA2 ≠ VSA3. The 
difference may be attributed to the change in density of the 
polymer matrix and hence the diffusional path length.
coated microspheres
The in vitro release profile of the coated microspheres 
in release medium of pH 2 revealed the absence of drug 
release for the 2 hours tested (Figure 6). In release studies 
conducted in phosphate buffer (Figure 6), where the pH was 
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Figure  4  scanning  electron  microscopy  photograph  of  formulation.  A)  VsA-1 
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gradually increased from 5.5 to 6.8, the drug release was 
negligible. However, as the pH of the release medium was 
raised beyond 7, the drug was released into the medium. 
This was expected, as Eudragit S100, an enteric copolymer 
made of methacrylic acid-methyl methacrylate, dissolves at 
a pH . 7. As the release medium pH was increased to 7.4, 
VSAE-1 microspheres showed around 12% drug release in 
a period of 2 hours against 4% drug release by VSAE-2. The 
amount of coating in VSAE-2 was larger, hence it took longer 
time to dissolve, as increased thickness of coating in tablets 
is known to affect oral bioavailability. However, 88% of the 
drug in VSAE-1 and 84% of that in VSAE-2 were found to 
be released at pH 7.4 in around 4.5–5 hours. The total drug 
release in the present case (88% and 84%) is better than that 
of coated microspheres of chitosan, where it was 82% and 
79%, as reported earlier.18
Drug release kinetics
The drug release data obtained from in vitro release experi-
ments were subjected to various kinetics equations to evaluate 
the drug release mechanism and kinetics. The kinetic models 
used were zero order (as cumulative amount of drug released 
versus time), first order (as log cumulative percentage of 
drug remaining versus time),25 and Higuchi model (as a 
cumulative percentage of drug released versus square root of 
time).26 Moreover, Hixson–Crowell cube root law27 was used 
to evaluate the drug release with changes in surface area and 
diameter of the particles while the mechanism of drug release 
was also evaluated by plotting first 60% of drug release in 
Korsmeyer and Peppas (K–P) equation,28 as log cumulative 
percentage of drug released versus log time, and the exponent 
“n” was calculated from the slope of the straight line. The 
release constants and regression coefficients (r2) for all the 
microsphere formulations using different kinetic equations 
are listed in Table 2.
A thorough analysis of the table revealed that in vitro 
release from the sodium alginate microspheres was best 
explained by the Higuchi equation, as the plots showed 
the highest linearity. This explains the reason for the slow 
diffusion rate as the distance for diffusion increases. The 
value of “n” as per the K–P model for all these microspheres 
was found to lie between 0.45 and 0.89, the range being 
indicative of anomalous behavior of drug release, where 
swelling, diffusion, and erosion play an important role.29,30 
The coated microspheres, on the other hand, demonstrated 
the first-order release, ie, Fickian kinetics and the value of 
“n” (,0.45) as per the K–P model also complement the same. 
The dissolution data when plotted as per Hixson–Crowell 
cube root law indicated a change in surface area and the 
diameter of the microspheres with progressive dissolution 
of the matrix as a function of time.
In vitro mucoadhesive properties
Estimation of in vitro mucoadhesion revealed that the time 
required for complete removal of microspheres from the 
mucosal tissue was 95 minutes, indicating good mucoadhesive 
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properties of alginate. Various polymer characteristics 
  necessary for mucoadhesion include the   presence of strong 
hydrogen bonding groups (–OH, –COOH), strong anionic 
charges, high molecular weight, sufficient chain flexibility, 
and surface free energy properties, favoring spreading onto 
mucus.31 The interaction between mucoadhesive polymer 
and mucous membrane can be described by the two steps 
in the adhesion process32 contact stage, where an intimate 
contact (wetting) occurs between mucoadhesive polymer 
and mucous membrane, and in the consolidation stage, where 
various physicochemical interactions occur to consolidate 
and strengthen the adhesive joint. Alginate is amongst the 
“first-generation” mucoadhesive polymer groups, a group 
that contains hydrophilic macromolecules with numerous 
hydrogen bond-forming groups.33–35 It is an anionic polymer 
with numerous carboxyl and hydroxyl groups. The mucous 
membrane secretes mucin that is rich in sialic acid and 
hexosamines. Mucin is also made up of sugars with a large 
number of hydroxyl groups. The concentrations of sialic acid 
and hexosamines are higher in mucin secreted by transitional 
mucosa that is immediately adjacent to colon tumor than the 
mucin secreted by normal mucosa.36 At colonic pH, sialic acid 
will remain deprotonated and will carry a negative charge. 
The free carboxyl group of calcium alginate will also be 
deprotonated at the said pH and thereby repel the negatively 
charged sialic acid moieties. However, alginic acid also 
contains a large number of hydroxyl groups, which will form 
hydrogen bonds with hydroxyl groups of mucin, imparting 
mucoadhesion. Similar hydrogen bonding and mucoadhesion 
would also result from amino groups of hexosamines.
Higher concentrations of sialic acid with hydroxyl groups 
and hexosamines in mucin adjacent to colon tumor may lead 
to higher mucoadhesion and hence a long residence time of 
the alginate microspheres adjacent to the tumor. However, it 
has already been reported that the time required to completely 
wash-off the valdecoxib-containing chitosan microspheres 
was quite long (162 minutes)18 compared with the similarly 
prepared microspheres of alginate (95 minutes). The better 
mucoadhesion with chitosan microspheres may be attributed 
to electrostatic attraction between positively charged chito-
san and negatively charged mucin and also to the hydrogen 
bonding due to the presence of –OH and deprotonated –NH2 
groups in chitosan.
Drug transport studies
MTT test
The color intensities of the wells were used as the   measure 
of survival of cells after various treatments. The percent-
age dehydrogenase activity was calculated by the fol-
lowing formula and plotted against the concentration 
(Figure 7): P = AT+/AT- × 100, where P is the percentage of 
dehydrogenase activity, AT+ is the absorbance of wells with 
test   solution, and AT- is the absorbance of wells without 
test solution.
The graph shows that the dehydrogenase activity of the 
cells with all the samples varied from a minimum of 82% 
to a maximum of 99%, indicating the absence of toxicity of 
valdecoxib and its coated microspheres to Caco-2 cells in the 
concentration range used (0.318–31.8 nM/mL).
Transport studies
The major mechanism for drug uptake across the intestinal 
mucosa is passive diffusion where the driving force is 
concentration gradient. Penetration through Caco-2 cells 
is well established as an in vitro model for evaluating 
transcellular transport.
Accordingly, Caco-2 cell monolayer was used as a model 
for studying the cellular uptake of free valdecoxib as well 
as valdecoxib entrapped in microspheres, but cell uptake 
will only take place if the cells are alive. Thus, initially, the 
cytotoxicity of the free drug as well as drug entrapped in 
microspheres was evaluated in the Caco-2 cell layer (MTT 
test), and it was observed that neither the free drug nor the 
entrapped drug interferes with cell metabolism. In other 
words, the drug does not have any cytotoxicity. The lack 
of cytotoxicity in Caco-2 cell layer appears to be due to 
Table 2 Fit for various drug and sodium alginate microspheres using different kinetic equations for describing release kinetics
Type of microsphere Zero order First order Higuchi K–P Model Cube root law
r2, K0(μg/hr) r2, K1(h-1) r2 KH(μg/h-1/2) r2, n, KKP(h-n) r2 KHC(μg1/3/min)
VsA-1 0.896, 0.7408 0.82, 0.163 0.987, 2.702 0.961, 0.59, 0.226 0.968, 0.191
VsA-2 0.884, 0.8639 0.971, 0.348 0.991, 3.178 0.984, 0.47, 0.345 0.991, 0.313
VsA-3 0.995, 0.7225 0.990, 0.136 0.978, 2.541 0.972, 0.76, 0.141 0.988, 0.169
VsA-4 0.911, 0.7832 0.988, 0.186 0.99, 2.836 0.978, 0.59, 0.234 0.968, 0.211
VsA-5 0.895, 0.7499 0.984, 0.170 0.985, 2.733 0.94, 0.599, 0.226 0.971, 0.197
VsAe-1 0.878, 0.8775 0.951, 0.348 0.935, 2.715 0.961, 0.28, 0.599 0.929, 0.336
VsAe-2 0.864, 1.47 0.880, 0.348 0.806, 5.551 0.943, 0.28, 0.618 0.915, 0.378International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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diminished expression of COX-2 by the Caco-2 cells.37,38 
It will be appropriate to mention here that Schiffmann et al39 
did not observe any cytotoxicity of valdecoxib in HCA-7 cells 
with high COX-2 expression. Thus, it is quite obvious that 
valdecoxib will not show any cytotoxicity in Caco-2 cells 
with diminished COX-2 expression.
The TEER was measured before and after the experiment. 
A small decrease (8%) in the TEER was observed. TEER 
(mean ± standard deviation), before and after experiments, 
was 269 ± 15 Ω cm and 247 ± 34 Ω cm, respectively, 
indicating that membrane integrity was not compromised 
during the study.
The transport of valdecoxib across Caco-2 cell monolay-
ers was studied under four conditions: valdecoxib solutions 
at pH 6.0 and 7.4 and valdecoxib microspheres at pH 6.0 and 
7.4. The results (Figure 8) suggest that there was no difference 
between the transport from the drug solutions at pH 6.0 and 
pH 7.4, indicating that the change in pH had no effect on the 
permeability of valdecoxib. This is   supported by the fact that 
valdecoxib, a sulfonamide, with pKa of 9.8, would remain 
in a unionized state at either pH. At 120 minutes the total 
amount transported from the solutions was 27% and 31%, 
respectively. The high degree of transport of valdecoxib is 
supported by a predicted logP of 2.734 and logD of 2.82 at 
both pH values. The transport of valdecoxib from coated 
microspheres was studied at pH 6.0 and pH 7.4. Valdecoxib 
could not be detected in the basolateral chamber when the 
microspheres were suspended in buffer at pH 6.0. This is 
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consistent with the in vitro release studies showing that no 
valdecoxib was released at pH , 7.
The transport across Caco-2 cell monolayers from valde-
coxib microspheres at pH 7.4 was slower than from solutions, 
probably due to the processes involved in hydration and 
dissolution of the coating layer and diffusion of valdecoxib 
out of the sodium alginate microspheres. Thus, a prolonged 
and sustained release profile was achieved.
The intracellular contents of valdecoxib after transport 
studies are represented in Figure 9. The intracellular contents 
of valdecoxib after transport studies for 120 minutes were 
significantly (P , 0.05) higher at pH 7.4 than after trans-
port studies with microspheres for 240 minutes. Thus, the 
microspheres yield a slower release and a lower intracellular 
content of valdecoxib. This indicates that the local delivery 
of valdecoxib to colon cancer cells bypasses the systemic 
delivery of the drug, and hence reduced cardiac side effects 
are possible by the multiparticulate system studied.
stability studies
Selected formulation VSAE-2 was subjected to   accelerated 
stability studies as per climatic zone IV condition for assessing 
long-term stability as per ICH protocol. After storage, the 
formulations were analyzed for the drug contents assay. No 
significant difference in drug contents was observed in the 
formulation. The degradation rate constant was found to be 
6.91E-05 day−1 and t90% was found to be 1534 days, indicat-
ing that the said formulation may have a shelf-life of more 
than 3 years.
Conclusion
The present work was aimed at exploitation of pH-sensitive 
polymer Eudragit S100 for colon-specific delivery of 
valdecoxib, a COX-2 inhibitor, and, further, at achiev-
ing mucoadhesion of the core microspheres by use of 
mucoadhesive polymer sodium alginate. The results of 
the present study indicate that the microspheres prepared 
using sodium alginate as a core and subsequently coated 
with Eudragit S100 could be used for the colon targeting of 
drugs. The presence of sodium alginate in the core imparts 
mucoadhesion in the colon after the removal of Eudragit coat 
by the mildly alkaline pH of colonic contents, which might 
lead to increased residence time of the drug in the affected 
area. The concepts of colon targeting and mucoadhesion have 
been tried with mixed results, and one of the reasons for the 
lack of stellar results might be that the assumed difference in 
ileum/colon pH is not large enough. However, the chances for 
success might be improved if the higher pH reported around 
the tumors means that the pH difference is bigger in colorectal 
cancer. We believe that further research efforts are warranted 
to assess the potential of COX-2 inhibitors in mucoadhesive 
microspheres targeted to release around colorectal tumors 
and eventually to ascertain the efficacy of the formulation 
in real-life situations.
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